Nature Communications (Feb 2021)
Common clonal origin of conventional T cells and induced regulatory T cells in breast cancer patients
- Maria Xydia,
- Raheleh Rahbari,
- Eliana Ruggiero,
- Iain Macaulay,
- Maxime Tarabichi,
- Robert Lohmayer,
- Stefan Wilkening,
- Tillmann Michels,
- Daniel Brown,
- Sebastiaan Vanuytven,
- Svetlana Mastitskaya,
- Sean Laidlaw,
- Niels Grabe,
- Maria Pritsch,
- Raffaele Fronza,
- Klaus Hexel,
- Steffen Schmitt,
- Michael Müller-Steinhardt,
- Niels Halama,
- Christoph Domschke,
- Manfred Schmidt,
- Christof von Kalle,
- Florian Schütz,
- Thierry Voet,
- Philipp Beckhove
Affiliations
- Maria Xydia
- RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg
- Raheleh Rahbari
- The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute
- Eliana Ruggiero
- Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre
- Iain Macaulay
- The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute
- Maxime Tarabichi
- The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute
- Robert Lohmayer
- RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg
- Stefan Wilkening
- Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre
- Tillmann Michels
- RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg
- Daniel Brown
- Department of Human Genetics, University of Leuven, KU Leuven
- Sebastiaan Vanuytven
- The Francis Crick Institute
- Svetlana Mastitskaya
- Medical Oncology Department, National Centre for Tumor Diseases
- Sean Laidlaw
- The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute
- Niels Grabe
- Medical Oncology Department, National Centre for Tumor Diseases
- Maria Pritsch
- Translational Immunology Department, German Cancer Research Centre
- Raffaele Fronza
- Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre
- Klaus Hexel
- Flow Cytometry Core Facility, German Cancer Research Centre
- Steffen Schmitt
- Flow Cytometry Core Facility, German Cancer Research Centre
- Michael Müller-Steinhardt
- German Red Cross (DRK Blood Donation Service in Baden-Württemberg-Hessen) and Institute for Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University
- Niels Halama
- Medical Oncology Department, National Centre for Tumor Diseases
- Christoph Domschke
- Department of Gynecology and Obstetrics, University Hospital of Heidelberg
- Manfred Schmidt
- Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre
- Christof von Kalle
- Translational Oncology Department, National Centre for Tumor Diseases and German Cancer Research Centre
- Florian Schütz
- Department of Gynecology and Obstetrics, University Hospital of Heidelberg
- Thierry Voet
- The Cancer, Ageing and Somatic Mutation Program, Wellcome Sanger Institute
- Philipp Beckhove
- RCI Regensburg Centre for Interventional Immunology, University and Department of Hematology/Oncology, University Medical Centre of Regensburg
- DOI
- https://doi.org/10.1038/s41467-021-21297-y
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 18
Abstract
The mechanisms that shape the regulatory T cell repertoire in patients with cancer are not completely understood. Here, the authors observe that, in breast cancer patients, tumor-resident regulatory T cells do not show clonal relationship with their circulating counterpart, but share a common origin with intratumoral antigen-experienced conventional T cells.
